Neuland Laboratories Ltd. (NEULANDLAB) AI Stock Analysis

• Market Cap: ₹166.81B
• Dividend Yield: 0.09%
• Average Volume (3M): 12.65K
• Price to Earnings (P/E): 94.7
• Beta (1Y): 0.62
• Revenue Growth: -18.66%
• EPS Growth: -47.59%
• Country: IN
• Employees: 1,643
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 10.81
• Shares Outstanding: 12,829,889
• 10 Day Avg. Volume: 4,848
• 30 Day Avg. Volume: 12,649
• PEG Ratio: -4.25
• Price to Book (P/B): 9.66
• Price to Sales (P/S): 9.98
• P/FCF Ratio: 132.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹14,863.50
• Price Target Upside: 11.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 65 Neutral
• Price Target: ₹13,977.00 ▲(5.17% Upside)

Neuland Laboratories' overall stock score reflects strong financial performance and a stable technical outlook. However, the high P/E ratio suggests potential overvaluation, which is a significant risk factor. The absence of earnings call and corporate events data limits additional insights into the company's future prospects.

Neuland Laboratories Ltd. Business Overview & Revenue Model

Company Description

Neuland Laboratories Ltd. (NEULANDLAB) is a pharmaceutical company based in India that specializes in the manufacturing and development of Active Pharmaceutical Ingredients (APIs). With a focus on research-driven innovation, the company serves global pharmaceutical markets by providing high-quality APIs across various therapeutic categories, including cardiovascular, central nervous system, and anti-infective segments. Neuland is recognized for its strong research and development capabilities and commitment to regulatory compliance.

How the Company Makes Money

Neuland Laboratories Ltd. generates revenue primarily through the production and sale of APIs. The company's revenue streams include contract manufacturing services, where it partners with international pharmaceutical companies to produce APIs as per specific requirements. Neuland's revenue is also supported by its own product portfolio, which includes a range of APIs developed in-house. The company benefits from strategic partnerships and long-term contracts with major pharmaceutical firms, enhancing its market presence and ensuring consistent demand for its products. Additionally, Neuland's focus on maintaining high regulatory standards and quality assurance helps in accessing developed markets, thus contributing significantly to its earnings.

Neuland Laboratories Ltd. Financial Statement Overview

Summary

Neuland Laboratories shows strong financial performance with significant revenue growth and improving margins. The balance sheet is robust with a healthy debt-to-equity ratio, although the increase in total debt requires monitoring. Cash flow management is sound but exhibits some variability.

Income Statement

Neuland Laboratories has demonstrated significant revenue growth over the past five years, with a notable jump from 2020 to 2024. Margins have generally improved, particularly the gross profit margin, indicating efficient cost management. However, net profit margins have seen mixed results, indicating potential volatility in net earnings. Overall, the income statement reflects a strong growth trajectory with some fluctuations in profitability.

Balance Sheet

The company's balance sheet is robust, with a strong equity position and a healthy debt-to-equity ratio, indicating prudent financial leverage. The equity ratio is high, which showcases stability and a solid asset base. However, there is a notable increase in total debt over recent years, which could pose a risk if not managed carefully. Overall, the balance sheet suggests financial stability with controlled leverage.

Cash Flow

Neuland Laboratories has shown consistent operating cash flow, supporting its operational needs. Free cash flow has improved significantly since 2020, although there was a decrease in 2025. The operating cash flow to net income ratio suggests efficient cash generation relative to net income. However, fluctuations in free cash flow growth indicate potential variability in cash generation capacity. Overall, cash flow management appears sound but with some variability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	14.77B	14.77B	15.59B	11.61B	9.23B	9.18B
Gross Profit	6.37B	7.26B	8.25B	5.47B	3.70B	3.63B
EBITDA	4.20B	4.20B	4.75B	2.79B	1.40B	1.63B
Net Income	2.60B	2.60B	3.00B	1.64B	638.22M	806.31M
Balance Sheet
Total Assets	21.80B	21.80B	18.33B	15.80B	13.83B	13.25B
Cash, Cash Equivalents and Short-Term Investments	3.67B	3.67B	1.03B	454.16M	84.68M	105.51M
Total Debt	1.57B	1.57B	953.90M	1.28B	2.41B	1.82B
Total Liabilities	6.55B	6.55B	5.50B	5.86B	5.43B	5.38B
Stockholders Equity	15.25B	15.25B	12.83B	9.94B	8.41B	7.86B
Cash Flow
Free Cash Flow	0.00	1.11B	1.18B	1.71B	-372.97M	839.65M
Operating Cash Flow	0.00	3.17B	2.61B	2.37B	603.89M	1.89B
Investing Cash Flow	0.00	-2.98B	-1.50B	-614.99M	-955.16M	-844.24M
Financing Cash Flow	0.00	249.61M	-692.82M	-1.36B	377.21M	-1.14B

Neuland Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13289.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NEULANDLAB, the sentiment is Positive. The current price of 13289.6 is below the 20-day moving average (MA) of 13682.02, above the 50-day MA of 12877.10, and above the 200-day MA of 13130.82, indicating a neutral trend. The MACD of 36.71 indicates Positive momentum. The RSI at 51.83 is Neutral, neither overbought nor oversold. The STOCH value of 40.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NEULANDLAB.

Neuland Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAPLIPOINT	75 Outperform	₹160.28B	28.36		0.26%	13.14%	18.21%
NATCOPHARM	74 Outperform	₹159.02B	9.37		0.68%	10.77%	36.14%
MARKSANS	69 Neutral	₹84.65B	24.18		0.43%	16.94%	4.90%
NEULANDLAB	65 Neutral	₹166.81B	94.70		0.09%	-18.66%	-47.59%
GRANULES	65 Neutral	₹107.01B	21.32		0.33%	-0.55%	23.68%
Sector *	51 Neutral	$7.41B	-0.29	-44.86%	2.30%	23.46%	-0.02%

Neuland Laboratories Ltd. Corporate Events

Neuland Laboratories Publishes Q1 2025 Financial Results

Neuland Laboratories Limited has announced the publication of its financial results for the quarter ending June 30, 2025. The results were published in the Financial Express and Andhra Prabha newspapers, in compliance with the Securities and Exchange Board of India regulations. This announcement is part of the company’s ongoing commitment to transparency and regulatory compliance, potentially impacting stakeholder confidence and market perception.